Press Releases & Presentations

 
(Swipe to view full table)
  Date Title and Summary View

May 15, 2012

Accelr8 and Denver Health Notified by Department of Defense for Rapid Diagnostics Award
DENVER, Colo., May 15, 2012 – Accelr8 Technology Corporation (NYSE MKT: AXK) and Denver Health received notice that the Defense Medical Research and Development Program (DMRDP) recommended $2 million funding of a proposed 35-month project submitted jointly by Denver Health and Accelr8. The DMRDP solicited proposals to "advance state-of-the...Read more

Apr 23, 2012

Accelr8 Attracts Up To $35 Million Private Equity Investment
DENVER, Colo., April 23, 2012 – Accelr8 Technology Corporation (Amex: AXK) announced today that an investment group formed by Jack Schuler, John Patience, and Larry Mehren will invest a total of up to $35 million in Accelr8's common stock. The purpose is to complete the product development and market introduction of Accelr8's BACcel™ ...Read more

Nov 22, 2011

Accelr8 Announces Development Expansion for Blood-Based Diagnostic Tests
DENVER, Colo., November 22, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced that it successfully completed two technical feasibility studies for test methods that expand its BACcel™ rapid diagnostic test library and automation capabilities. The first is a same-day multi-pathogen, multiple drug resistance diagnostic pa...Read more

Oct 13, 2011

Accelr8 Announces Interim Plan and Advanced Studies
DENVER, Colo., October 13, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced that upon reaching the end of its technology evaluation agreement with Novartis (Sep 30, 2011), discussion has now shifted to searching within Novartis for funding vehicles. This transition follows Novartis business analyses and successful Proof of ...Read more

Sep 22, 2011

Accelr8 Announces Renewal and Expansion of SCHOTT Microarray License, and Notice of Allowance for New Patent
DENVER, Colo., September 22, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced that Accelr8 and SCHOTT Technical Glass Solutions, GmbH (Jena, Germany) have renewed Accelr8's license to SCHOTT for Nexterion┬« microarraying slides using OptiChem┬« biocoatings. In addition to renewing the existing non-exclusive license, Accelr8 a...Read more

Sep 19, 2011

Accelr8 Announces Results in Award-Winning Presentation for Rapid Diagnostics with ICU Specimens
CHIGACO, Ill., September 19, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced results presented at the 51st ICAAC held in Chicago on September 17. As previously announced in July, the presenters received an award for an "outstanding presentation of an abstract accepted by ICAAC." The presentation title is "Same-Shift ID Dir...Read more

Jul 25, 2011

Accelr8 Announces Continuation and Expansion of BACcel Development Collaboration
DENVER, Colo., July 25, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced that Accelr8 and Novartis have extended their program agreement through September 30, 2011. Having reviewed new data, Novartis will now install a system in their own facility to expand development capacity. While this project proceeds, the companies wi...Read more

Jul 18, 2011

Accelr8 to Receive Award for ICAAC Presentation
The presentation title is "Same-Shift ID Directly from Respiratory Specimens by Automated Microscopy." It will report results from a study using Accelr8's BACcel™ rapid diagnostic system in collaboration with investigators at the Barnes-Jewish Hospital in St. Louis. Accelr8 will announce the study results at the time of the presentation. ...Read more

Jun 30, 2011

Accelr8 Announces Continuation of BACcel Collaboration
DENVER, Colo., June 30, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced that the company agreed to extend its letter of intent with its industry collaborator, based on prepaid R&D expenses, for one month to July 31, 2011. The collaborator stated the companies' joint intent to complete evaluation of Accelr8's data and agree...Read more

May 23, 2011

Accelr8 4-Hour Test Identifies New Drug-Resistant "Staph" (hVISA) Undetectable by Hospital Labs
DENVER, Colo., May 23, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced results from two studies presented at ASM 2011 (American Society for Microbiology, www.asm.org) held in New Orleans. Authors included principal investigators from Denver Health and from the Barnes-Jewish Hospital in St. Louis. The annual ASM General Mee...Read more
FirstPrevious
1
...
4
5
6
7
Next Last

= add release to Briefcase
NASDAQ: AXDX
$ 30.30
+0.75
(2.54%)
4:00 PM ET on Jun 22, 2017
Day High: 30.40
Day Low:  28.90
Volume:    435,013
Delayed ~20 min., by eSignal.

Want to receive investor-related news and updates?

Join our mailing list

Other updates